GOLDEN-RT A Paradigm Shift in Systemic Cancer Radiotherapy: ‘Golden’ Nanoplatform for Pharmacokinetic Precision and Universal Metabolic Targeting
- Coordinator
- Bar Ilan University, Israel
- Runs
- 1 July 2026 to 31 December 2027
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101292561
What the project is doing
In the project's own words, from its summary on CORDIS.
Systemic radiotherapy, achieved by coupling radionuclides to cancer-targeting agents, has shown remarkable therapeutic success. Yet this success has not translated to most solid tumors, largely as no suitable targeting ligands exist and due to a fundamental pharmacokinetic mismatch between antibodies (long half-life) and therapeutic radionuclides (short half-life). Triple-negative breast cancer (TNBC) is a particularly aggressive and devastating malignancy.
Its rapid progression, and high mortality rate once metastatic, have created an urgent, unmet need for new systemic radiotherapy options in oncology. In our ERC-CoG project, we are developing gold nanoparticles (GNPs) that harness insulin for delivery of antibodies across biological barriers. Building on our results, we have developed GOLDEN-RT, a GNP nanoplatform that aligns circulation time with radionuclide half-life, enabling precise, systemic delivery of radiation to both primary tumors and micrometastases.
GOLDEN-RT combines metabolic targeting, exploiting the overexpressed insulin receptor for deep tumor penetration, together with antibody recognition for robust tumor selectivity. Our preliminary results are promising, demonstrating efficient radiolabeling with in vivo stability and safety, pharmacokinetic matching, high intra-tumoral accumulation as well as selective targeting of metastases, while sparing healthy surrounding cells.
Here, we aim to demonstrate proof-of-concept efficacy and safety of GOLDEN-RT conjugated with clinically relevant radionuclides in TNBC models in vivo. In parallel, we intend to achieve business readiness by consolidating the IP strategy, performing comprehensive market analysis, engaging key clinical and industry stakeholders, and defining a clear commercialization strategy. This project will establish a versatile systemic radiotherapy platform with potential to transform TNBC treatment and adapting to other aggressive solid tumors.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Bar Ilan University | Ramat Gan | Israel | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI